Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

PURPOSE:We previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is not superior to FOLFOX4 in patients at advanced stage of colorectal cancer with liver metastases. Here we aimed to determine whethe...

Full description

Bibliographic Details
Main Authors: Zeinab Hamidou, Benoist Chibaudel, Mohamed Hebbar, Marine Hug de Larauze, Thierry André, Christophe Louvet, David Brusquant, Marie-Line Garcia-Larnicol, Aimery de Gramont, Franck Bonnetain
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4910973?pdf=render

Internet

http://europepmc.org/articles/PMC4910973?pdf=render

Similar Items